Corticotropin-releasing factor (CRF) and cholecystokinin (CCK), two highly colocalized neuropeptides, have been linked to the etiology of stress-related anxiety disorders. Recent evidence points to the possibility that some of the anxiogenic effects of the central CCK system take place through interplay with the CRF system. The aim of the present study was to examine the effects of chronic, mild activation of CRF receptor 1 (CRF 1 ) on the central CCK system of the C57BL/6J mouse. As shown by in situ hybridization, real-Time PCR and immunohistochemistry, 5 days of intracerebroventricular (i.c.v.) injections of a subeffective dose (2.3 pmol) of cortagine, a CRF 1 -selective agonist, resulted in an increase in CCK mRNA levels and CCK 2 receptor immunoreactivity in several brain regions, such as amygdala and hippocampus, known to be involved in the regulation of anxiety. Mice with elevated endogenous central CCK tone exhibited significantly higher anxiety-like behaviors in the open-field task and elevated plus maze, and enhanced conditioned fear. These behavioral changes were reversed by i.c.v. administration of the CCK 2 -selective antagonist LY225910, after 5 days of priming with cortagine. Under the same conditions, the intraperitoneal administration of the CRF 1 antagonist antalarmin was ineffective. This result indicated that once the CCK system was sensitized by prior CRF 1 activation, it exhibited its anxiogenic effects, without influence by CRF 1 , possibly because of its observed downregulation. In sum, our results provide a novel model for the interaction of the CRF and CCK systems contributing to the development of hypersensitive emotional circuitry.
Introduction
Several neurotransmitters and neuropeptides have been implicated in the etiology of stress-related anxiety disorders. Among them are cholecystokinin (CCK) and corticotropin-releasing factor (CRF).
1,2 The neuropeptide CCK originally discovered as a gut peptide has been identified in the mammalian brain. 3 The most abundant form, the C-terminally sulfated octapeptide fragment of CCK, exerts its action through two G-protein coupled receptor subtypes CCK receptor 1 (CCK 1 ) and CCK receptor 2 (CCK 2 ). CCK 2 is mostly found in the CNS, whereas CCK 1 is highly abundant in the gastrointestinal tract, but has also been identified in the CNS. The CCK precursor is also cleaved into other biologically active fragments such as cholecystokinin tetrapeptide (CCK4) and pentagastrin (CCK5). [4] [5] [6] Exogenous administration of CCK4 or CCK5 provoke panic attacks in man. 1, 6 Patients with panic disorder are hypersensitive to CCK 2 receptor stimulation in comparison with healthy volunteers and patients with other anxiety disorders. They also appear to differ from healthy subjects in CCK processing and thus final CCK forms. 1, 6 The anxiogenic potential of the CCK system in animal models of anxiety is also well documented. CCK 2 receptor agonists increase anxiety of mice and rats in the elevated plus-maze test (EPM) and light-dark compartment test (LDT). 4, 5, 7 Rats selected on the basis of high anxiety-like behaviors in the EPM display an increased density of CCK 2 . 8 Mice lacking CCK 2 show reduced anxiety in EPM and LDT. 9 CRF, a 41-residue neuropeptide mediates many behavioral responses to stress. 10, 11 It exhibits its actions through two distinctly distributed G proteincoupled CRF receptor subtypes, CRF receptor 1 (CRF 1 ) and CRF receptor 2 (CRF 2 ). 12,13 CRF can be anxiogenic or anxiolytic. Mice with targeted deletion of either the CRF 1 gene 14, 15 or the CRF 2 gene, 16, 17 display reduced or heightened anxiety-like behavior, respectively. These data suggest that activation of CRF 1 increases, and activation of CRF 2 predominantly attenuates anxiety. A series of studies provides important behavioral models that link the CRF system in conjunction with the CCK central system to the etiology of anxiety disorders. 18, 19 It is shown that repeated infusion of a subthreshold dose of the CRF receptor agonist urocortin 1 (Ucn1) into the basolateral nucleus of the amygdala (BLA) produces longlasting anxiogenic effects, as indicated by EPM and social interaction test of anxiety. 19 Furthermore, repetitive administration of subthreshold doses of Ucn1 results in a 'priming' phenomenon. Once primed, these animals exhibit a strong increase in blood pressure, respiratory rate and heart rate in response to intravenous administration of sodium lactate, a panicogenic agent in humans. 19 Thus, in the present study, utilizing the 'priming' procedure, we tested the possibility that the CRF system is capable of elevating the endogenous CCK tone, in key brain regions, such as amygdala and hippocampus, known to be involved in the regulation of innate and conditioned anxiety responses. We report that repeated stimulation of CRF 1 resulted in an increase in CCK mRNA and CCK 2 immunoreactivity in the BLA and dentate gyrus, as well as in the elevated anxiety-related behaviors in CCK 2 -dependent manner. Together, our data provide a plausible pathological model of the chronic, but mild stimulation of the CRF system, as it may occur under stress conditions, enhancing the sensitivity of the CCK system through a feed forward mechanism.
Materials and methods

Animals
C57BL/6J mice aged 9 weeks (Centre D'Elevage, Le Genest St Isle, France) were used. The mice were individually housed in standard Macrolon cages (Type 2: 22 Â 16 Â 13 cm) and maintained on a 12 h light/dark cycle (lights on at 0700 hours) with food and water freely available. The experiments were performed in the Max Planck Institute for Experimental Medicine and in the John A Burns School of Medicine, University of Hawaii. All experimental procedures were in compliance with the European Council Directive (86/609/EEC) by permission of the Animal Section Law enforced by the District Government of Braunschweig, Lower Saxony, Germany. Experiments performed in Honolulu were approved by the University of Hawaii Animal Care Committee in accordance with National Institute of Health guidelines. All efforts were made to minimize animal suffering.
Cannulation and administration of drugs
The injection system (C235; Plastics One, Roanoke, VA, USA) consisted of a double-guided cannula, dummy and a cap. The cannulae were implanted under 1.2% avertin anesthesia (0.4 ml per mouse) into both lateral brain ventricles (anteroposterior (AP): 0.5 mm, lateral 1 mm, depth 2 mm) and affixed to the skull by dental cement. The animals were allowed to recover for 7-10 days before the experiments started. On the day of the first experiment, the mice were exposed to a light isoflurane anesthesia, the cap and the dummy were removed and peptide solutions were delivered through an injector linked to two Hamilton microsyringes with plastic tubing. The peptides were administered bilaterally by a microinjector (CMA/ Microdialysis, Solna, Sweden) over a 30 s period so that 0.25 ml volume was injected to each side. The cannula placement was verified for each mouse immediately after the behavior experiments by histological examination of the brains following methylene blue injection (0.25 ml per site). Only data obtained from mice with correctly inserted cannulae were included in the statistical analysis. Cortagine was synthesized as described previously. 20 It was initially dissolved in 10 mM acetic acid and diluted 1:2 with sterile saline (0.9% NaCl). The CCK 2 -selective agonist CCK4 (Bachem, Heidelberg, Germany) and the anta-
(Tocris Cookson Ltd, Bristol, UK) were first dissolved in saline (0.9% NaCl) to a concentration of 100 mM. For cannulae injection the stock solutions were further diluted in saline to their final concentrations. The CRF 1 -selective antagonist antalarmin (Ant; N-Butyl-N-ethyl- [2, 5, 6 ,-trimethyl-7-(2,4,6-trimethylphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]amine) was purchased from Sigma (St Louis, MO, USA) and dissolved in a solution of 10% cremaphor (Sigma), 5% ethanol, and 85% sterile saline with a final pH of 6.0. The vehicle was made as above with the omission of Ant. The number of mice in behavioral experiments per group was 7-12. The number of mice in each experiment is specified in the corresponding figure legends.
Acute administration of the drugs For acute treatments, mice received injections of CCK4, cortagine or vehicle, bilaterally into the lateral ventricles, as described above. After 30 min, the mice were exposed to training for fear conditioning or were behaviorally tested in the post-shock freezing, or EPM and open-field test (OFT). Antagonists or vehicle, were injected 30 min before the agonists. The choice of behavioral paradigms, was based on the fact that they are the most frequently used, and the most thoroughly validated in the assessment of the roles of the central CRF and CCK systems in the regulation of innate anxiety (EPM, OFT) and learned fear (postshock freezing, fear conditioning).
Chronic administration of the drugs
For chronic treatment with cortagine, the C57BL/6J mice were divided into two groups on experimental day 1. Group 1 received a subeffective dose of 10 ng (2.3 pmol) cortagine i.c.v., whereas Group 2 was administered vehicle (saline). Cortagine was selected in view of its ability to mediate CRF 1 -specific anxiety in EPM, without CRF 2 -mediated side effects. It was determined that 25-30 ng of the peptide was the smallest dose eliciting significant anxiogenic effects. Under these conditions, 10 ng of cortagine was tested, but was subeffective. 20 On experimental days 1-4 both groups were injected with cortagine or saline, respectively, and returned to their cages after each injection. On day 5 both groups were further subdivided after receiving a fifth injection of either saline or cortagine. Thirty minutes later, the groups either received saline, a subeffective dose of CCK4 (10 ng; 15.8 pmol), or 250 ng (0.5 nmol) of the CCK 2 -selective antagonist LY225910 (LY; 250 ng; 495 pmol). All doses represented the total amount applied per mouse in a volume of 0.5 ml. Half of the total amount was infused (i.c.v) with a microinjector (CMA/Microdialysis), over a period of 30 s, into each side. On the basis of the sequence of injections, the groups were called Saline-Saline (Sal-Sal), Saline-CCK4 (Sal-CCK4), Saline-LY (Sal-LY), CortagineSaline (Corta-Sal), Cortagine-CCK4 (Corta-CCK4) and Cortagine-LY (Corta-LY; Figure 3f , protocol scheme). The LY225910 dose used was selected on the basis of dose response studies in rats. 23 The efficacy of the dose used to block of CCK4-mediated behavioral effects was confirmed in a control experiment with mice. Thirty minutes after the injection of the second compound (CCK4, LY225910 or saline), the mice were subjected to EPM, OFT, post-shock freezing test or training for fear conditioning. The inhibitor dose applied prevented the CCK4 actions ( Figure 2) .
In a related experiment, the ability of Ant, a CRF 1 -specific antagonist, 24 to prevent behavioral effects mediated by CRF 1 , was tested. The mice were divided into two groups on experimental day 1, and treated for 4 days with cortagine or saline. On day 5, the groups were treated intraperitoneally (i.p.) with Ant or vehicle, 30 min before both groups received a fifth and final injection of saline or cortagine (protocol scheme, Figures 8e and i) . Totally, four groups were generated: Vehicle-Saline (Veh-Sal), Vehicle-Cortagine (Veh-Corta), Ant-Saline (Ant-Sal) and AntCortagine (Ant-Corta). The Ant dose used (10 mg kg
À1
) was selected on the basis of its ability to prevent behavioral effects of cortagine. Thirty minutes after the fifth injection of saline or cortagine, the mice were subjected to EPM, OFT, post-shock freezing test or training for fear conditioning.
Post-shock freezing
The mice were placed in a Plexiglas chamber (36 Â 21 Â 20 cm 3 ) with a metal floor grid and overhead houselights (12 V, 10 W halogen lamp, 100-500 lux). In the chamber, a high-frequency loudspeaker (KT-25-DT; Conrad, Hirschau, Germany) provided constant background noise (white noise, 68 dB sound pressure level (SPL)). After a 3 min adjustment period to the chamber, an electric footshock (2 s, 0.7 mA, constant current) was administered. The relative duration (%) of freezing defined as a cessation of all body movements except those required for respiration and heart beat, was determined for 5 min immediately after the final shock in the chamber where the footshock was given. It was recorded by two unbiased observers in 10 s intervals. Locomotor activities and the percentage of the explored area were automatically monitored by an infrared beam system and analyzed using software developed in collaboration with TSE (Bad Homburg, Germany).
Fear conditioning
The training (conditioning) consisted of a single trial. The mice were exposed to the conditioning context (180 s) identical to the one described under 'Postshock freezing.' This exposure was followed by a footshock (unconditioned stimulus (US), 0.7 mA, 2 s, constant current) delivered through a stainless steel grid floor. The mice were removed from the fear conditioning box 30 s after shock termination to avoid an aversive association with the handling procedure. The fear-conditioning chamber was thoroughly cleaned with 70% ethanol before each animal was tested. Memory tests were performed 24 h after fear conditioning. Contextual memory was tested in the fear-conditioning box for 180 s without US presentation, with the presence of background noise. Freezing as an index of long-term memory, was recorded as described under Post-shock freezing, above. The activity burst produced by the electric shock was automatically detected by an infrared beam system and analyzed by software developed in collaboration with TSE.
Elevated plus maze
The behavior of mice was recorded by a video camera connected to a PC and analyzed by TSE software In-situ hybridization of mouse CCK mRNA C57BL/6J mice were divided into two groups. One group received a subeffective dose of 10 ng cortagine 20 i.c.v. (Corta group), and another group was administered vehicle (saline; Sal group) each day for 4 days. On day 5, the mice were decapitated 30 min after receiving the last injection of either cortagine or saline (cortagine-injected, saline-injected mice, respectively). As a second control group naiveuntreated mice (N) were employed. Brains were removed, and frozen ( Figure 5a ). Coronal brain sections (20 mm thick) from two mice and sagittal brain sections from three mice collected from each experimental group were obtained with a microtome, thaw-mounted onto SuperFrost Plus slides (Fischer, Pittsburgh, PA, USA), fixed in 4% paraformaldehyde in phosphate buffer (PFA), followed by washing in phosphate-buffered saline (PBS), and dehydration in a graded series of ethanol. An oligonucleotide probe complementary to mouse CCK mRNA (5 0 -CTAGGAC TGCCATCACCACGCACAGACATACGCCGCTCTT-3 0 ) was end labeled at 37 1C for 10 min using terminal deoxynucleotidyl transferase kit (Roche, Mannheim, Germany). The sections were incubated overnight in hybridization buffer (50% formamide, 10% dextran sulfate, 50 mM DTT, 0.3 M NaCl, 30 mM Tris HCl (pH 7.4), 4 mM EDTA (pH 8), IX Denhardts solution, 0.5 mg ml À1 salmon sperm DNA and 0.5 mg ml À1 Poly A DNA). Post-hybridization washes were carried out in 1 Â standard sodium citrate (SSC; 150 mM NaCl, 30 mM Na citrate, pH 7.2) for 2 Â 2 min at room temperature, followed by a stringent wash at 57 1C in 1 Â SSC for 45 min. The slides were subsequently washed in progressively diluted SSC buffers and then dehydrated in aqueous ethanol (50-100%).
The slides were air dried and exposed to Kodak Biomax MR-Roentgen film for 24 h. The images were then transferred to the AIDA densitometric analysis software (version 3.2). For the purpose of quantifying mRNA levels, a 1.5 mm 2 area was defined and placed in five different positions over the pyramidal cell layer of the CA1 and CA3 regions. The mean value over those five measures was included in the statistical data analysis. A second area of 3 mm 2 was used to analyze the other brain regions in the same way, and specific signal density was determined relative to neutral background density. Equivalent planes of coronal and sagittal sections 25 were used for comparison of animal groups. Values are expressed in arbitrary units (mean integral density/area background). As the arbitrary values did not differ from those of coronal (two for each group) and sagittal (three for each group) sections, these data were collapsed. The final statistical analysis for each brain region combined 3-5 sections from each treatment group, depending on the availability of comparable sections.
Immunohistochemical analysis of CCK 2
In the first 4 days of the experiment, two groups of mice were treated as described under In-situ hybridization of mouse CCK mRNA. The Corta group, Sal group, and naive control group each consisted of four mice. Thirty minutes after the last injection on day 5, the mice were anesthetized with a 1.2% avertin solution injected i.p., and transcardially perfused with ice-cold PBS (pH 7.4) followed by 4% PFA (pH 7.4, 150 ml per mouse). The brains were postfixed for 48 h in the same fixative (4% PFA) and then immersed for 24 h each in 10, 20 and 30% sucrose in PBS. The brains were cryosectioned into 50 mm slices. Elimination of endogenous peroxidase activity was accomplished using 1% H 2 O 2 in methanol for 15 min, followed by rinses in PBS containing 0.2% Triton-X 100 (TBS). Five percent goat serum and 0.3% TBS in 0.01 M PBS was used for preincubation. Sections (50 mm thick) were then incubated (24 h) with primary antibody (1:200) in TBS containing 5% goat serum. The CCK 2 antibody was purchased from Lifespan Biosciences (Woburn, MA, USA; now MBL Labs; cat no: LS-A1282). Subsequently, the sections were incubated with biotinylated anti-rabbit antibody (1:500) followed by the avidin-biotin complex (Vector ABC kit). For visualization, diaminobenzidine (DAB) was used as chromogen (Sigma tablet set). The sections were mounted on glass slides, dehydrated, and covered with Eukitt. The staining of the brain sections was quantified using the NIH Image software as described previously. 26 Briefly, the same threshold was applied for each section, and the number of CCK 2 -containing cells was counted automatically. The counting was performed in an area of the same shape and size for each brain region. Cells were counted individually and monitored as number of CCK-containing cells per 0.1 mm 2 area. For immunofluorescence analysis, a similar protocol as the one used for perfusion and postfixation of mice brains was followed. The naive control group was omitted, since this group did not differ from the saline-treated group in the pilot experiment. The cortagine-and saline-treated groups consisted of four mice, each. Double immunofluorescent labeling was performed for CRF and CRF 1 proteins following the manufacturer's protocol (Vector Labs, Burlingame, CA, USA). Briefly, sections were washed with TBS before overnight incubation at 4 1C with primary CRF antibody (1:5000) (rabbit anti-CRF antibody, Peninsula Laboratories Inc., Belmont, CA, USA), followed by incubation with biotinylated anti-rabbit secondary antibody (1:4000; Vector Labs). The sections were washed, Fluorescin avidin DCS (Vector Labs) was applied, rendering green fluorescence. Following several washes in TBS, staining for CRF 1 (1:400; goat anti-CRF 1 (C-16), Santa Cruz Inc., Santa Cruz, CA, USA) was performed, using a similar procedure as that for CRF. CRF 1 was visualized by incubation with biotinylated anti-goat secondary antibody (1:400) (Rockland Immunochemicals Inc, Gilbertsville, PA, USA), followed by Texas red avidin DCS (Vector Labs). The sections were mounted on Superfrost Plus slides (Menzel Glåser, Braunschweig, Germany) using Vectashield mounting medium (Vector Labs) to prevent photo bleaching. Single immunofluorescent staining was carried out for CCK 2 (1:400; rabbit anti-CCK 2 (H85), Santa Cruz Inc.) and CRF 2 (1:400) proteins (goat anti-CRF 2 (LS-A3570), LifeSpan Biosciences) using the same protocol as that used for CRF, except for the antibodies applied, followed by fluorescent labeling using Texas red Avidin DCS and Fluorescein avidin DCS (Vector Labs), respectively.
An Axioimager Zeiss microscope and Zeiss Axio Cam HRM camera were used for the observations and photography of the slides, respectively. Equally sized images from different treatment groups were analyzed using AIDA imaging software. For this quantification, a defined area was placed over the regions of interest and specific signal density was determined. To account for differences in background staining intensity, two background intensity measurements lacking immunofluorescent profiles, were taken from each section. The mean of these two measurements constituted the background intensity. The background intensity was then subtracted from the measured specific signal density to provide a final immunofluorescence intensity value. Values are expressed in arbitrary units (quantum level/area; QL mm À2 ).
Laser-capture microdissection and real-time quantitative PCR
Quantitative gene expression data of CCK, CCK 2 , CRF, CRF 1 and CRF 2 were obtained with RT-PCR of total RNA extracted from the BLA and dentate gyrus of the cortagine (Corta) and saline-treated (Sal) groups (three mice per group) by laser-capture microdissection (LCM). Thirty minutes after receiving a fifth injection of saline or cortagine, the mice were rapidly decapitated, the brains were extracted, snap frozen, and sectioned coronally at a thickness of 20 mm on a cryostat. Glass slides carrying brain sections were loaded in a version of PixCell II called Autopix Microdissection Microscope (CFG, University of Albany, NY, USA), and cells from the dentate gyrus and BLA were collected in microcaps using the 60 Â objective. The laser spot size was 25 mm in diameter. The laser power and pulse varied between 60-100 mW and 1600-2500 msec, respectively. Pictures before and after laser capture were taken. The cells were processed immediately after microdissection. RNA was extracted using the Qiagen RNeasy microkit (Qiagen, Valencia, CA, USA), and genomic DNA was removed with integrated on-column DNase digestion using RNAse-free DnaseI (Qiagen). RNA quality was verified with the Agilent 2100 Bioanalyzer. cDNA synthesis was carried out using SuperScript III FirstStrand Synthesis System for RT-PCR (Invitrogen, Karlsruhe, Germany), following instructions provided by the manufacturer. Primer pairs for RT-PCR were generated to amplify 180-200 bp fragments of the genes of interest using the web-based application Primer 3. The following primers were used: CCK,
and CRF 1 (PPM04312A) (real-time PCR primers, Superarray Biosciences). b-Actin was used as control. cDNA synthesized from 250 ng of mRNA was amplified with the LightCycler FastStart DNA Master SYBR Green I kit (Roche, Indianapolis, IN, USA). The PCR was carried out in a LightCycler 2.0 (Roche, Indianapolis, USA). Real-time results were analyzed using the Roche LightCycler software (Roche LightCycler, version 2.1) with automatic computation of baseline and threshold fluorescence levels. Results of real-time PCR data were represented as C t values, with C t defined as the threshold cycle of PCR at which the amplified product was first detected. Gene expression C t values below those of endogenous controls were discarded from the analysis, and outlier removal was performed in cases where the standard deviation of C t values exceeded 0.3 cycles. Melting curve analysis showed a single component confirming the formation of a specific PCR product. All real-time reactions were carried out in triplicate. The data were analyzed using equation in which mean fold change in target gene expression = 2 ÀDDC t . DDC t was calculated as (Mean Ct, target -Mean Ct, b-actin) Â Corta group À (Mean Ct, target À Mean Ct, b-actin) Â Sal group. Corta group represented the mean expression of the target gene in the BLA or DG after 5 days of five injections of cortagine, and Sal group represented the mean expression of the target gene after five injections of Saline, normalized to b-actin as an endogenous control. The variance estimated from the replicate C t values was carried through to the final calculation of relative quantities using standard propagation of error methods. In the final calculation, the error was estimated by evaluating the 2 ÀDDC t term using DDC t ± s.d. (Table 1) . 27 Statistics Statistical evaluation (StatView 5.0.1 software; SAS Institute, Cary, NC, USA) was performed by one-way analysis of variance (ANOVA), with Bonferroni/Dunn test applied, post hoc, for individual between-group comparisons at the P < 0.05 level of significance. Data are expressed as mean ± s.e.m.
Results
Dose-dependent modulation of anxiety-related behaviors by CCK4
In our initial experiments, the dose-dependent effect of CCK4 on post-shock freezing and context-dependent fear conditioning was established by intracerebroventricular (i.c.v.) injection of C57BL6/J mice 30 min before training with different CCK4 doses (Figure 1a ). Statistical analysis (one-way ANOVA followed by the Bonferroni/Dunn test) revealed that CCK4 dose-dependently impaired immediate post-shock freezing (F (4,35) = 10.89; P < 0.05; Figure 1b) , without affecting context-dependent long-term freezing (F (4,35) = 1.84; P > 0.05; Figure 1c ). Immediate post-shock freezing was applied as a measure of short-term conditioned fear, while freezing on the test day, 24 h later, was used Table 1 Gene expression of CRF and CCK systems as determined with real-time PCR is altered in the cortagine-treated mice in comparison with saline-treated controls in the dentate gyrus and BLA Abbreviations: BLA, basolateral nucleus of the amygdala; CCK, cholecystokinin; CRF, corticotropin-releasing factor; Corta, cortagine; Sal, saline.
Values > 1 are indicative of an increase, and < 1 a decrease, in gene expression relative to the saline-treated control. The error term was estimated by evaluating the 2 DDCt term using DDC t plus the standard deviation and DDC t minus the standard deviation. The asymmetric distribution is a consequence of converting the results of an exponential process into a linear comparison of amounts. The number of mice per group was three. Real-time reactions were carried out in triplicate. as indicator of long-term conditioned fear. It should be noted that immediate post-shock freezing can also be regarded as a measure of general anxiety if the context used does not represent a specific stimulus. 28 The lowest dose of CCK4 peptide per mouse that produced significant impairment on post-shock freezing was 25 ng CCK4 (39.5 pmol; Bonferroni/Dunn test, P < 0.05 vs saline). In view of the specificity of CCK4 selectively binding to CCK 2 , 29 it was concluded that the postshock freezing deficit was mediated by CCK 2 .
We also investigated dose-dependent effects of CCK4 on anxiety by monitoring the EPM behavior of C57BL/6J mice after i.c.v. injection of the peptide (Figures 1d-f Figure 1f ). CCK4 did not (F (4,32) = 1.11; P > 0.05) elicit changes in locomotor activity as indicated by the total distance traveled in EPM (data not shown).
To determine whether the dose of the CCK 2 -selective antagonist LY225910 (495 pmol), established as effective in previous studies in rats, 23 is capable of inhibiting the anxiogenic effects of an acute CCK4 application in mice, we injected 495 pmol of LY225910, i.c.v., 30 min prior to administration of 100 ng CCK4 (158 pmol). The mice were tested 30 min afterwards in EPM. As expected, CCK4 (158 pmol), decreased the time spent in the open arms (F (3,34) = 11.85; P < 0.05; Bonferroni/Dunn test, P < 0.05 vs Sal-Sal; Figure 2a ) and number of entries (F (3,34) = 4.95; P < 0.05; Bonferroni/Dunn test, P < 0.05 vs Sal-Sal; Figure 2b ) into the open arms of EPM, without eliciting significant locomotor effects (F (3, 34) = 0.22; P > 0.05; Figure 2c ). Post hoc analysis revealed that 495 pmol of LY225910 completely blocked the effects of CCK4 on anxiety-like behaviors in EPM (Bonferroni/Dunn test, P > 0.05 vs Sal-Sal). To determine if LY225910 had a behavioral effect when injected alone, mice were acutely administered 495 pmol LY225910 (LY-Sal group), a dose found to block anxiogenic effects of CCK4
Changes in anxiety levels after repeated stimulation of CRF 1 reflect changes of endogenous tone and sensitivity of the CCK system Previous studies demonstrated that repeated administration of the CRF receptor subtype-nonspecific agonist Ucn1 into the BLA of the rat resulted in a long-lasting increase in anxiety-like behaviors. 18, 19 On the basis of these findings we hypothesized that repeated stimulation of CRF 1 may result in hyperexcitability of anxiety circuits through either an elevated endogenous CCK tone or reduced thresholds for activation of the CCK system. 29, 30 Therefore six groups were generated (Sal-Sal, Sal-CCK4, Sal-LY, Corta-Sal, Corta-CCK4, Corta-LY; see Materials and methods and Figure 3f , protocol scheme). With the Corta-Sal group the possibility was tested that repeated stimulation of CRF 1 resulted in increased anxiety-like behaviors. With the Corta-CCK4 group the possibility was tested whether repeated stimulation of CRF 1 led to a changed threshold for activation of the CCK system, while with the Corta-LY group the possibility was tested that increased anxiety-like behaviors were CCK 2 dependent. We found that the Corta-Sal and Corta-CCK4 groups displayed significantly enhanced anxiety-like behavior as indicated by decreased time spent (F (5,57) = 5.12; P < 0.05; Bonferroni/Dunn test, P < 0.05 vs Sal-Sal; Figure 3a) and number of entries (F (5,57) = 4.2; P < 0.05; Bonferroni/Dunn test, P < 0.05 vs Sal-Sal; Figure 3b ) into the open arms of EPM. Importantly, this increase in anxiety disappeared in the Corta-LY group (Bonferroni/Dunn test, P > 0.05 vs Sal-Sal; Figures 3a and b) . The locomotor activity of Corta-Sal and Corta-CCK4 mice was not affected in the EPM test (F (5,57) = 1.18; P > 0.05; Bonferroni/Dunn test, P > 0.05 vs Sal-Sal; Figure 3c ). Interestingly, Corta-CCK4 mice also displayed decreased time spent into the open arms of EPM (Bonferroni/Dunn test, # P < 0.05 vs Corta-Sal; Figure 3a ) when compared to Corta-Sal mice. This result was suggestive that repetitive stimulation of CRF 1 enhanced the sensitivity of the CCK system to facilitate anxiety-like behavior.
Furthermore, the Corta-Sal and Corta-CCK 4 groups spent significantly less time in the central areas of the OF (F (5,54) = 5.83; P < 0.05; Bonferroni/Dunn test, P < 0.05 vs Sal-Sal; Figure 3e ) and exhibited more peripheral region activity (F (5,54) = 5.68; P < 0.05; Bonferroni/Dunn test, P < 0.05 vs Sal-Sal) than the Sal-Sal group (Figure 3d ). These data strongly suggested that the Corta-Sal and Corta-CCK4 groups showed a more anxious response than the Sal-Sal control group in these tests. The Corta-LY group did not reduce the central activity or increase the peripheral activity as observed with the Corta-Sal and Corta-CCK4 groups (Bonferroni/Dunn test, P < 0.05 vs Sal-Sal; Figures 3d and e) . The overall results from EPM and OFT suggested that chronic stimulation of CRF 1 led to a CCK 2 -dependent increase of anxiety measures, mediated by endogenous release of CCK, in the exploratory models of anxiety.
Changes in fear conditioning after repeated stimulation of CRF 1 reflects changes of the endogenous CCK system In addition, we used the same procedure to investigate post-shock freezing, a putative measure of short-term conditioned fear. Post-shock freezing was determined immediately after administration of the electric shock. Long-term freezing, indicating long-term memory, was . The Corta-LY group showed an increase in the total distance traveled (cm; c) in the elevated-plus maze. In addition, the Corta-Sal and Corta-CCK4 groups spent significantly more time in peripheral areas (d), and less in central areas (e) in the open-field task. Peripheral and central activities of the Corta-LY group showed the opposite pattern (10-11 mice per group). Statistically significant differences: Bonferroni/Dunn test, *P < 0.05 relative to control (Sal-Sal); # P < 0.05 relative to Corta-Sal group. measured 24 h after training (Figure 4c , schematic protocol). The Corta-Sal and Corta-CCK4 mice showed significant impairment of post-shock freezing (F (5,54) = 4.74; P < 0.05; Bonferroni/Dunn test, P < 0.05 vs Sal-Sal; Figure 4a ) and enhancement of long-term freezing (F (5,54) = 8.17; P < 0.05; Bonferroni/Dunn test, P < 0.05 vs Sal-Sal; Figure 4b ). As in the anxiety models described, both impairment of contextual post-shock freezing and enhancement of long-term freezing were prevented by the CCK 2 -specific antagonist LY225910, as demonstrated with the behavior of the Corta-LY group (Bonferroni/Dunn test, P > 0.05 vs Sal-Sal). In view of the observed effects of the selective CCK 2 antagonist LY225910, it was suggested that these actions were mediated by the endogenous CCK system.
We also considered the possibility that the 'priming' procedure altered the responsiveness of the mice to the footshock serving as US. This consideration implied that the enhancement of contextual conditioned fear, observed in the Corta-Sal group, might be due to higher sensitivity to the footshock. 'Priming' with cortagine did not change the footshock reactivity during training for fear conditioning (F (1,18) = 0.33; P > 0.05 vs Sal-Sal; Figure 4c ). It was concluded that, the conditioned, but not the unconditioned fear response was affected in the Corta-Sal group.
Elevated CCK mRNA levels in the brain regions involved in CCK-induced anxiety after repeated stimulation of CRF 1 We directly tested the hypothesis that the observed behavioral effects resulted from changes in the expression of the CCK gene in the brain regions that have been implicated in CCK-induced anxiogenic behavior. 4, 5 Repeated stimulation of CRF 1 (Corta group; Figure 5a ) via the brain ventricles evoked a marked rise in CCK mRNA levels in the frontal cortex (FCtx; F (2,12) = 8.71; P < 0.05), ventral part of the CA1 region of the hippocampus (F (2,11) = 74.48; P < 0.05), dentate gyrus (F (2,11) = 7.21; P < 0.05), lateral nucleus of amygdala (LA) and BLA (F (2,10) = 83.55; P < 0.05), lateral posterior (LP; F (2,12) = 19.66; P < 0.05), medial geniculate (MGN; F (2,12) = 27.33; P < 0.05) and ventral posteromedial (VPM; F (2,12) = 18.13; P < 0.05) nuclei of the thalamus (Bonferroni/Dunn test, P < 0.05 vs Sal group; Figure 5b) . Micrographs of the in situ hybridizations using an antisense probe for CCK mRNA are shown on sagittal (lateral 2.04 mm bregma; Figure 5c ), and coronal sections (À1.58 mm bregma; Figure 5d ). Other areas rich in CCK-containing neurons that have been implicated in regulation of anxiety-like behaviors, 31, 32 like the cortical, basal and medial nuclei of amygdala, bed nucleus of the stria terminalis, laterodorsal and paraventricular nuclei of the thalamus, cingulate and piriform cortical areas, did not differ significantly in CCK mRNA levels (data not shown).
Increase of CCK 2 protein levels in the BLA and dentate gyrus after repeated stimulation of CRF 1 We also addressed the question whether the increased CCK mRNA levels, possibly causing an increase in the secretion of CCK-like peptides, were associated with changes in the production of the CCK 2 receptor protein (Figure 6a ). An immunhistochemical analysis showed that CCK 2 immunoreactive cells were densely Figure 4 Repeated stimulation of corticotropin-releasing factor receptor 1 (CRF 1 ) leads to cholecystokinin receptor 2 (CCK 2 )-dependent changes in short-and long-term conditioned contextual fear. All groups of mice were treated as described in concentrated in the forebrain, most notably in the regions of the hippocampus and the cortex, and sparsely distributed in the thalamic region (Figures 6c  and d) . The CCK 2 protein production in the dentate gyrus subregion of the hippocampus (F (2,9) = 5.91; P < 0.05) and BLA (F (2,9) = 4.95; P < 0.05) of the Corta group was significantly higher than in the Sal group (Bonferroni/Dunn test, P < 0.05) (Figures 6b-d) . A similar tendency was found in cortex and LA. However, no statistically significant difference between the groups was found (Bonferroni/Dunn test, P > 0.05 vs Sal group; Figures 6b-d) . Quantitative analysis of the optical density of CCK 2 in the dentate gyrus (F (1,6) = 6.12; P < 0.05; P < 0. Interestingly, overlapping distributions of upregulated CCK mRNA and increased CCK 2 immunoreactivity were found only in the dentate gyrus, a subregion of the hippocampus and in the BLA.
Thalamic nuclei, hippocampal and cortical regions with increased levels of CCK mRNA after chronic cortagine treatment, showed very small or no differences in the production of CCK 2 receptor protein after the same treatment. Together, the data from in situ hybridization and immunohistochemical staining experiments supported the hypothesis that the dentate gyrus and BLA were the major candidate sites where changes in endogenous CCK tone could mediate the anxiogenic effects of chronic CRF 1 stimulation.
Changes in anxiety levels and fear conditioning after repeated stimulation of CRF 1 are not prevented by blockade of CRF 1 It had to be considered that the 5-day treatment with a subthreshold dose of cortagine resulted in a changed CRF system responsiveness that, together with changes in the endogenous CCK system, could be responsible for the observed anxiety and conditioned fear enhancement. The anxiety-like behavior following the administration of CRF into the brain ventricles, Figure 5 Repeated stimulation of corticotropin-releasing factor receptor 1 (CRF 1 ) increases cholecystokinin (CCK) mRNA in discrete brain regions. The experimental procedure is shown under (a). Densitometric analysis of CCK mRNA of cortagine (Corta group) and saline-treated (Sal group) mice. These two groups were generated as described under (a). A significant upregulation of CCK mRNA was observed in various brain regions 5 days after daily repeated administration of (2. Immunofluorescent labeling for cholecystokinin receptor 2 (CCK 2 ) protein indicates its upregulation in the dentate gyrus and BLA. The experimental procedure is the same as described in Figure 6a . Conventional fluorescent photomicrographs illustrating changes in the density of CCK 2 -labeled (red) cells (see white arrows) following chronic (5 days) cortagine (Corta group) or saline (Sal group) administration are presented. A significant increase was observed in the dentate gyrus (a) and in the BLA (b) 5 days after repeated administration of (2.3 pmol) 10 ng cortagine. Brain regions shown: granular layer of dentate gyrus (grDG); polymorphic layer of dentate gyrus (poDG) and basolateral nuclei of amygdala (BLA). Coronal sections from the Sal group (a and b, left), and from the Corta group (a and b, right). Scale bar, 200 mm (a) and 400 mm (b). The background intensity was subtracted from the calculated intensity of the selected region and resulting signal intensity was divided by the area. Mean fluorescence is expressed in arbitrary units (quantum level/area; QL per mm 2 ) (c). Each group, 4 mice. Statistically significant differences: *P < 0.05, Bonferronni/Dunn test, relative to control (salinetreated mice).
appears to be mediated through CRF 1 , 20 while CRF 2 activation, outside the lateral septum, appears to mediate anxiolytic behavior. 17 First, we tested the dose of Ant, a CRF 1 -selective antagonist, that is capable of blocking the anxiogenic effects of 100 ng cortagine (23 pmol Figure 8d ; Bonferroni/Dunn test, Ant10-Corta vs SalSal; P > 0.05, Ant20-Corta vs Sal-Sal; P > 0.05). Post hoc analysis, also revealed that administration of 10 or 20 mg kg À1 Ant alone, i.p., 30 min before testing in EPM did not affect anxiety-like behaviors in the EPM test (Bonferroni/Dunn test, Ant10-Sal vs Sal-Sal; P > 0.05 for all three behavioral measures in EPM; Ant20-Sal vs Sal-Sal; P > 0.05 for all three behavioral measures in EPM, Figures 8b-d) .
The involvement of CRF 1 receptor in the 'priming' process was established with the 5-day injection protocol as described in Materials and methods, with Figure 8f ) and number of entries (F (3, 33) = 2.26; P < 0.05; Bonferroni/ Dunn test, P < 0.05 vs Veh-Sal; Figure 8g ) into the open arms of EPM. Importantly, these increases in anxiety were not blocked in the Ant-Corta group (Bonferroni/Dunn test, P < 0.05 vs Veh-Sal; Figures 8f  and g ). The locomotor activity was not affected in the EPM test (F (3,33) = 1.18; P > 0.05; Bonferroni/Dunn test, P > 0.05 vs Veh-Sal; Figure 8h ). These data suggested that stimulation of CRF 1 elevated the endogenous CCK tone and increased anxiety-like behaviors in a CCK 2 -dependent fashion. CRF 1 itself, however, was not directly involved, under these conditions, in the regulation of the same behaviors.
Similar to the results obtained in the EPM test, antagonism of CRF 1 by 10 ng kg À1 of Ant did not block the cortagine 'primed' decrease (F (3, 34) = 4.42; P < 0.05; Bonferroni/Dunn test, Ant-Corta vs SalCorta; P < 0.05; Figure 8j ) or increase (F (3,34) = 6.38; P < 0.05; Bonferroni/Dunn test, Ant-Corta vs SalCorta; P < 0.05; Figure 8k ) of post-shock or long-term freezing, respectively.
Repeated stimulation of CRF 1 leads to downregulation of the CRF 1 protein level in BLA In addition, we examined whether repeated stimulation of CRF 1 resulted in changed expression patterns of CRF and its receptor subtypes in the BLA, central nucleus of amygdala (CeA), dentate gyrus and CA1 subregions of the hippocampus. Five days of cortagine treatment, resulted in a significantly decreased production of CRF 1 protein in the BLA (F (1,6) = 9.86; P < 0.05; P < 0.05 vs Saline; Figures 9b and c) . No statistically significant changes in CRF 1 protein levels were found in the CeA, CA1 and dentate gyrus subregions of the hippocampus (Figures 9b, c and  10b ; P > 0.05 vs Saline). In contrast to the decreased production of CRF 1 , chronic cortagine treatment did not lead to changes in the production of CRF peptide and CRF 2 protein in the BLA, CeA or CA1 and dentate gyrus subregions of the hippocampus (Figures  9a, c, d , 10a and c; P > 0.05 vs Saline), as observed by densitometric analysis of CRF, CRF 1 and CRF 2 immunoreactivity (Figure 11 ).
CCK, CCK 2 , CRF, CRF 1 and CRF 2 genes are differentially expressed after cortagine 'priming' as indicated by RT-PCR of microdissected tissue LCM in combination with RT-PCR was employed to check the expression of CCK, CCK 2 CRF, CRF 1 and CRF 2 genes in the dentate gyrus and BLA of the saline-treated (Sal group) or cortagine-treated (Corta group) mice. Resulting C t values were recorded for each gene of interest as well as for the reference gene (b-actin). Results for the target genes were normalized to the reference gene. Comparison of the expression of the target genes in the dentate gyrus and BLA of the Sal-and Corta groups was determined with the deltadelta (DD)C t method. 27 The fold changes of the genes expressions is presented in Table 1 . The RT-PCR analysis provided corroborative evidence for upregulation of the CCK and CCK 2 mRNA of the Corta group, in both dentate gyrus and BLA. Interestingly, RT-PCR data indicated moderate downregulation for CRF 2 in the dentate gyrus, as well as strong downregulation for both CRF and CRF 1 mRNA in the BLA of the Corta group. Only, the latter result was confirmed by immunofluorescence analysis of their respective protein levels.
Discussion
In this study, we examined the effects of chronic administration of the newly developed CRF 1 agonist cortagine 20 on the CCK system. For this purpose we employed a previously described 'priming' paradigm. 18, 19 Evidence was provided that 5-day i.c.v. administration of a subthreshold dose of cortagine, is capable of elevating the endogenous central CCK tone, known to be involved in the modulation of anxiety disorders. 5, 6 Mice with elevated CCK tone showed an anxiogenic behavioral profile in EPM and OFT, and displayed impairment of post-shock freezing, together with enhancement of long-term contextual conditioned fear. Selective blockade of CCK 2 with LY225910 prevented these behavioral effects. Repeated CRF 1 stimulation, which resembled the repeated exposure to a mild, chronic stressor, leading to an increased CCK tone, might be a model for anxiety disorder. This view is supported by the findings that the best predictor of a CCK-induced panic attack in humans, in laboratory provocation experiments, is a preexisting state of anxiety provoked by recent stressful life events. 1, 30, 33 From an ethological point of view, it would make sense that the emotional state of generalized anxiety lowers the threshold for the elicitation of an anxiety response in the event that danger is detected.
Several lines of research in rodents have already indicated that the basal CCK tone in the brain may play an important role in enhancing anxiogenic factors. It has been observed that CCK 2 agonists produce pronounced anxiogenic effects only in stressed but not in unstressed animals. 34 In addition, after exposure to an acute stressor, both CCK immunoreactivity and CCK 2 density in the hippocampus are increased. 7, 35 It is conceivable that an elevated CCK tone was associated with these treatments. Moreover, the level of anxiety in EPM is Figure 10 Immunofluorescent labeling for corticotropinreleasing factor (CRF), CRF 1 and CRF 2 indicates no hippocampal changes in response to the chronic cortagine treatment. Mice were injected with saline (a-c, left) or cortagine (a-c, right). The experimental procedure is the same as described in Figure 6a . Representative photomicrographs illustrating changes in the number of CRF-, CRF 1 -and CRF 2 -labeled cells following chronic (5 days) cortagine (Corta group) or saline (Sal group) administration are presented. No significant changes in CRF, CRF 1 and CRF 2 immunoreactivity were observed in the dentate gyrus and CA1 subregions of hippocampus after 5 days of repeated administration of (2.3 pmol) 10 ng cortagine. CRF immunoreactivity (green; see red arrow; a); CRF 1 immunoreactivity (red; see white arrow; b); CRF 2 immunoreactivity (green; see yellow arrow). CA1, CA1 subregion of hippocampus; CA3, CA3 subregion of hippocampus; grDG, granular layer of dentate gyrus; poDG, polymorphic layer of dentate gyrus; bar, 200 mm (a and b); bar, 400 mm (c). Figure 11 Repeated stimulation of corticotropin-releasing factor receptor 1 (CRF 1 ) leads to a decrease of the CRF 1 production in the BLA. Quantitative densitometric analysis of mean immunofluorescence of CRF, CRF 1 and CRF 2 in the BLA and dentate gyrus, as shown in Figures 9 and 10 . The background intensity was subtracted from the calculated intensity of the selected region, and resulting signal intensity was divided by the area. Mean fluorescence is expressed in arbitrary units (quantum level/area; QL mm À2 ). The number of mice per group was 4. Statistically significant differences: *P < 0.05, Bonferroni/Dunn test, relative to control (saline-treated mice).
correlated with an increased CCK tone, as indicated by a higher CCK 2 binding activity in the hippocampus and cortex in anxious compared to nonanxious controls, 8 and upregulation of CCK 2 immunoreactivity in the basolateral amygdala of rats with elevated anxiety. 36 In addition, anxiety responses after cat exposure among various rat strains can be attributed to a correlated cortical production of CCK 2 . 37 Recently, it was observed that mice with inducible overexpression of forebrain CCK 2 exhibit a significantly increased CCK 2 binding capacity and anxietylike behaviors in the open-field and social interaction tests. 38 These findings indicate that the anxiety level may be dynamically regulated by the stress-related CCK tone.
Importantly, behavioral differences between 'cortagine-stimulated' and control animals were paralleled by changes in CCK mRNA levels and CCK 2 immunoreactivity in brain regions demonstrated to be involved in the regulation of anxiety-like behaviors. 39, 40 The areas with overlapping elevation of CCK mRNA and CCK 2 immunoreactivity were the dentate gyrus subregion of the hippocampus and BLA. We hypothesize that these areas could be the major sites of behavioral effects observed after chronic stimulation of CRF 1 . In support, it is well established that chronic stimulation of BLA CRF receptors with a subthreshold dose of Ucn1 induces a type of plasticity called 'priming'. 18, 19 Once 'primed,' rats exhibit enhanced responsiveness that persists for 30 days to panicogenic sodium lactate and N-methyl-D-aspartate (NMDA) receptor-dependent anxiogenic responses in the EPM and social interaction tests. 18, 19 In addition, using in situ hybridization and quantitative receptor autoradiographical techniques CCK mRNA, CCK 2 protein and mRNA have been localized within BLA, 41, 42 and injection of nonselective CCK agonists into BLA, produce anxiogenic responses of both rats and mice in EPM. 42, 43 There are no previous studies elucidating the role of dentate gyrus in CRF or CCKrelated anxiety. However, dentate gyrus is well connected with BLA 44, 45 and seems to be an important structure in gating the formation of memory that renders emotional significance for the organism. [46] [47] [48] [49] In our study, acute injections of CCK4 increased anxiety-like behaviors in the EPM and OFT tests. Thereby, the well established role of the CCK system in exploratory models of anxiety [4] [5] [6] was confirmed. Interestingly, the same treatment resulted in impairment of post-shock freezing, without affecting longterm contextual fear memory. Other studies performed with CCK 2 antagonists or CCK 2 -deficient mice in fear conditioning models provide ambiguous results. It has been reported that CCK 2 antagonists exhibit either a decreasing 50 or no 5 effect on fear conditioning. Similarly, fear conditioning was not changed in CCK 2 -deficient mice. 51 Chronic injection of cortagine did not only result in an increase of nonassociative forms of anxiety, but also increased the ability to learn and retain negative associations in context-dependent fear conditioning. On this basis, it is suggested that 'cortagine-treated' mice represent a model of anxiety, which also includes a heightened responsiveness to negative associations. Moreover, both acute injection of CCK4 and the cortagineinduced elevated CCK tone resulted in reduced post-shock freezing, regarded as a measure of shortterm conditioned fear. It is possible that activation of CCK 2 -induced changes in the anxiety-related reactivity and processing of a novel conditioning context, which led to impaired post-shock freezing. 52 Within the amygdala, acute stress and anxiety-like behaviors are associated with an increase in the production and release of CRF acting through CRF 1 . [53] [54] [55] Also, acute i.c.v. administration of CRF results in a modest increase of CRF 1 mRNA expression in the BLA. 56 We have found that chronic administration of cortagine downregulated CRF 1 protein in the BLA, without concomitant changes in CRF and CRF 2 production as indicated by immunoreactivity. It is tempting to speculate, that the role of CRF 1 in regulating BLA neurons may be gradually reduced when the system is adapted, which suggests that CRF 1 may have a potent influence on adjusting behavioral responses to acute stress conditions, but not during chronic stress. In line with this reasoning, administration of the CRF 1 -selective antagonist, Ant, was not capable of blocking the behavioral effects of chronic stimulation of CRF 1 . It is, therefore, suggested that chronic stimulation of CRF 1 enhanced the sensitivity of the CCK system to promote changes in anxiety-like behaviors. However, once such mechanism was set into the motion, CRF 1 was probably no longer directly involved in the regulation of anxiety, possibly because of its observed downregulation.
CRF might exhibit positive effects on CCK tone directly or indirectly. A direct action of CRF may have evolved through CRF 1 receptors that are known to be present in BLA, and different subregions of the hippocampus, cortex or thalamus. 12, 13 Animal studies indicate that CRF may play a role in the anxiogenic 57 and endocrine 58 actions of CCK. A recent in vitro study in which AtT-20 cells, a cellular model of corticotrophs, were used, demonstrated that CRF is capable of strongly inducing the expression of the CCK gene in a CRF 1 -dependent manner. 59 Indirectly, CRF interacts with several neurotransmitter systems, including the serotonergic, 60 dopaminergic 61 and GABAergic systems. 62 Similarly, CCK is colocalized with dopamine, 63 serotonin 64 and GABA 65 in different brain areas, and CCK actions on anxiety regulation can be mediated through interaction with these neurotransmitter systems. 4 It is conceivable that stimulating actions of CRF in these areas of colocalization induce differential synthesis and/or release of CCK. It is suggested that such actions may represent a mechanism through which CCK has modulatory influence on anxiety-related behaviors. 4, 5 Such interaction with CCK would present a novel element in the CRF function, which goes beyond the early phase of the stress response, 66, 67 and involves long-lasting changes in other neuropeptide systems.
The demonstration of the role of chronic CRF 1 stimulation in anxiety in this study not only further confirms 'priming' as a valid pharmacological anxiety model in the mouse, 18, 19 but also reveals its role in profound sensitization of the central CCK system, thus projecting a novel molecular mechanism for the expression of anxiety. This feed-forward sensitization, in addition to contributing to an increased anxiety, also changes the aversive learning capacity. These changes could conceivably trigger the development of different psychopathological forms. Therefore, we propose that CRF 1 priming and consequent elevation of the CCK tone represent an important mechanism by which concurrent changes in two neuropeptide systems can translate the effects of mild and chronic stress into psychopathological responses. If so, nonpeptidic CRF 1 and CCK 2 antagonists could have major effects in preventing the spiral of stressinduced sensitization of the emotional circuitry.
